KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Depreciation & Amortization (CF) (2017 - 2025)

Bionano Genomics' Depreciation & Amortization (CF) history spans 7 years, with the latest figure at $2.4 million for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 57.79% year-over-year to $2.4 million; the TTM value through Sep 2025 reached $9.6 million, down 37.0%, while the annual FY2024 figure was $14.0 million, 2.29% up from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $2.4 million at Bionano Genomics, roughly flat from $2.4 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $5.6 million in Q3 2024 and bottomed at $448000.0 in Q1 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $2.4 million (2024), against an average of $2.5 million.
  • The largest annual shift saw Depreciation & Amortization (CF) soared 393.3% in 2022 before it crashed 57.79% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.9 million in 2021, then surged by 48.63% to $2.8 million in 2022, then soared by 30.01% to $3.6 million in 2023, then crashed by 33.31% to $2.4 million in 2024, then decreased by 0.92% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Depreciation & Amortization (CF) are $2.4 million (Q3 2025), $2.4 million (Q2 2025), and $2.4 million (Q1 2025).